First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt turns negative
Q1 FY2026 net debt was -$248.47M, compared with $0 a year earlier.
Context
- Net debt amounted to 85.5% of total assets at the end of Q1 FY2026.
- Net debt grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (224.08M) USD
- Year-over-year change
- -109.3%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (224.08M) | -109.3% |
| FY2024 | 2024-12-31 | (107.04M) | -489.7% |
| FY2023 | 2023-12-31 | (18.15M) | — |
Net Debt vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 net debt of -$248.47M is the 9th highest of the 10 companies compared; the peer median is -$26.68M.
- Net debt amounts to 85.5% of total assets for TRAX, versus a peer median of 13.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.89M | +134.8% | — | 8.8% | |
| Jun 2026 | -$3.14M | -215.0% | — | 1.3% | |
| Mar 2026 | -$5.6M | +26.5% | — | 3.8% | |
CLYMClimb Bio, Inc. | Mar 2026 | -$7.88M | +72.4% | — | 5.2% |
| Mar 2026 | -$26.68M | +4.3% | — | 13.4% | |
| Jun 2026 | -$28.5M | — | — | 22.2% | |
| Mar 2026 | -$186.21M | -1297.0% | — | 98.1% | |
| Mar 2026 | -$197.69M | -0.9% | — | 49.4% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | -$248.47M | — | — | 85.5% |
| Sep 2026 | -$722.27M | -38.4% | — | 94.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | -$26.68M | +1.7% | — | 13.4% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.